Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | MGAM | O43451 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SI | P14410 | 1/20 | 0.32 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.32 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7835353 | 0.92 | ALDH1A1 (0.40) | ALDH1A1LMNAHSD17B10PIN1ALOX15 | |
| SCHEMBL3908512 | 0.86 | ALDH1A1 (0.42) | ALDH1A1LMNAHSD17B10PIN1ALOX15 | |
| SCHEMBL6028711 | 0.86 | ALDH1A1 (0.42) | ALDH1A1LMNAHSD17B10PIN1ALOX15 | |
| SCHEMBL9770041 | 0.84 | ALDH1A1 (0.40) | ALDH1A1LMNAHSD17B10PIN1ALOX15 | |
| SCHEMBL10502342 | 0.80 | CYP1A2 (0.35) | ALDH1A1LMNAHSD17B10SMN1; SMN2 | |
| SCHEMBL2148474 | 0.79 | ALDH1A1 (0.48) | ALDH1A1LMNAHSD17B10PIN1ALOX15 | |
| Potassium Ion SCHEMBL8993919 | 0.77 | SOAT1 (0.32) | ALDH1A1SOAT1CYP3A4TSHRNFKB1 | |
| SCHEMBL9110564 | 0.77 | CYP3A4 (0.33) | ALDH1A1SOAT1CYP3A4TSHRNFKB1 | |
| SCHEMBL7432060 | 0.77 | ALDH1A1 (0.46) | ALDH1A1LMNAHSD17B10PIN1ALOX15 | |
| SCHEMBL6208557 | 0.76 | THRB (0.40) | ALDH1A1LMNAHSD17B10ALOX15MGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431717-B2 | Process for the preparation of 5-(2-ethyl-dihydro-1H-inden-2-yl)-1H-imidazole and salts thereof | JSC GRINDEKS (LV) | 2013-04-30 | — | — | US | disclosed |
| EP-2225209-B1 | PROCESS FOR THE PREPARATION OF 5-(2-ETHYL-DIHYDRO-1H-INDEN-2-YL)-1H-IMIDAZOLE AND SALTS THEREOF | GRINDEKS JSC (LV) | 2012-03-28 | — | — | EP | disclosed |
| US-20110028733-A1 | PROCESS FOR THE PREPARATION OF 5-(2-ETHYL-DIHYDRO-1H-INDEN-2-YL)-1H-IMIDAZOLE AND SALTS THEREOF | JSC GRINDEKS (LV) | 2011-02-03 | — | — | US | disclosed |
| CN-101889003-A | Process for the preparation of 5-(2-ethyl-dihydro-1h-inden-2-yl)-1h-imidazole and salts thereof | GRINDEKS JSC | 2010-11-17 | — | — | CN | disclosed |
| EP-2225209-A1 | PROCESS FOR THE PREPARATION OF 5-(2-ETHYL-DIHYDRO-1H-INDEN-2-YL)-1H-IMIDAZOLE AND SALTS THEREOF | Grindeks, a joint stock company (LV) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009071584-A1 | PROCESS FOR THE PREPARATION OF 5-(2-ETHYL-DIHYDRO-1H-INDEN-2-YL)-1H-IMIDAZOLE AND SALTS THEREOF | GRINDEKS, A JOINT STOCK COMPANY (LV) | 2009-06-11 | — | — | WO | disclosed |
| EP-0310745-B1 | SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR PREPARATION AND USE | ORION-YHTYMÄ OY (FI) | 1993-01-27 | — | — | EP | disclosed |
| EP-0183492-B1 | SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR PREPARATION AND USE | Farmos-Yhtyma Oy (FI) | 1989-11-15 | — | — | EP | disclosed |
| EP-0310745-A2 | Substituted imidazole derivatives and their preparation and use | ORION-YHTYMÄ OY (FI) | 1989-04-12 | — | — | EP | disclosed |
| US-4689339-A | 4-dihydroinden-2-yl-, 4-tetrahydronaphth-2-yl-, and 4-dihydrobenzofuran-2-ylimidazoles, useful to block α2 -adrenergic receptors | FARMOS YHTYMA OY (FI) | 1987-08-25 | — | — | US | disclosed |
| EP-0183492-A1 | Substituted imidazole derivatives and their preparation and use | Farmos-Yhtyma Oy (FI) | 1986-06-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028733-A1 | PROCESS FOR THE PREPARATION OF 5-(2-ETHYL-DIHYDRO-1H-INDEN-2-YL)-1H-IMIDAZOLE AND SALTS THEREOF | CYP3A5, CYP3A4, IPO5 | ALDH1A1 190/4885LMNA 3506/4885HSD17B10 848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.